Transgene Biotek announced that a novel drug for liver cancer developed by its scientists has shown excellent efficacy in the latest animal studies. This affirms the earlier data gathered from in-vitro studies.
The company claims that the technology involves highly selective knock-down of specific liver cancer producing gene targets, which has demonstrated remarkable regression of the tumours in the animal studies.
For comments and feedback: editorial@rttnews.com